Skip to main content
ImmuneCited

Resolution of inflammation: Intervention strategies and future applications.

Jeneen Panezai, Thomas E Van Dyke
Other Toxicology and applied pharmacology 2022 20 인용
PubMed DOI
<\/script>\n
`; }, get iframeSnippet() { const domain = 'immunecited.com'; const params = 'pmid\u003D35644268'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Study Design

연구 유형
Other
대상 집단
None
중재
Resolution of inflammation: Intervention strategies and future applications. None
대조군
None
일차 결과
None
효과 방향
Mixed
비뚤림 위험
Unclear

Abstract

Chronic inflammatory diseases are the major cause of morbidity and mortality in the aging population worldwide. Chronic inflammation reflects a deficiency in the resolution phase of the acute inflammatory response, which then fails to engage the adaptive immune system accordingly. Resolution of inflammation is a tightly regulated biological pathway that sequentially aids in eliminating the inducing agent and orchestrates clearance of effete immune cells to promote the return to tissue homeostasis. The lipid mediators of resolution of inflammation comprise a family of specialized pro-resolving mediators (SPMs). The synthesis of SPMs occurs via enzymatic conversion of essential omega-6 (n-6) and omega-3 (n-3) fatty acids. SPMs have anti-inflammatory, pro-resolving and tissue regenerating properties. A large number of in vitro and in vivo studies have unveiled the mechanism of action of many SPMs. Here, we focus on the actions of SPMs in health and chronic disease models as well as their potential as therapeutic agents in ongoing and future clinical trials.

요약

This work focuses on the actions of pro-resolving mediators (SPMs) in health and chronic disease models as well as their potential as therapeutic agents in ongoing and future clinical trials.

Used In Evidence Reviews

Similar Papers